株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

東部ウマ脳炎 : パイプライン分析

Eastern Equine Encephalitis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321904
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.77円で換算しております。
Back to Top
東部ウマ脳炎 : パイプライン分析 Eastern Equine Encephalitis - Pipeline Review, H2 2016
出版日: 2016年12月30日 ページ情報: 英文 36 Pages
概要

東部ウマ脳炎は、蚊が媒介となる感染症であり、アルボウイルスである東部ウマ脳炎ウイルスが原因です。発熱、頭痛等の軽度な症状から、錯乱・失見識・こん睡など重篤なものまで広い症状が現れます。

当レポートでは、東部ウマ脳炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

東部ウマ脳炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • AlphaVax, Inc.
  • AltraVax Inc.
  • EpiVax, Inc.
  • Profectus BioSciences, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤のプロファイル

  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • TSI-GSD-104

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8887IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eastern Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Eastern Equine Encephalitis (Infectious Disease) pipeline landscape.

Eastern equine encephalitis is a disease that is spread to humans by infected mosquitoes. Eastern equine encephalitis is caused by the eastern equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eastern Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eastern Equine Encephalitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eastern Equine Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Eastern Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Eastern Equine Encephalitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eastern Equine Encephalitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eastern Equine Encephalitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eastern Equine Encephalitis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eastern Equine Encephalitis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eastern Equine Encephalitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eastern Equine Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Eastern Equine Encephalitis - Overview
    • Pipeline Products for Eastern Equine Encephalitis - Comparative Analysis
  • Eastern Equine Encephalitis - Therapeutics under Development by Companies
  • Eastern Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Eastern Equine Encephalitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Eastern Equine Encephalitis - Products under Development by Companies
  • Eastern Equine Encephalitis - Products under Investigation by Universities/Institutes
  • Eastern Equine Encephalitis - Companies Involved in Therapeutics Development
    • Altravax Inc
    • EpiVax Inc
    • Profectus BioSciences Inc
  • Eastern Equine Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSI-GSD-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Eastern Equine Encephalitis - Dormant Projects
  • Eastern Equine Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Eastern Equine Encephalitis, H2 2016
  • Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Eastern Equine Encephalitis - Pipeline by Altravax Inc, H2 2016
  • Eastern Equine Encephalitis - Pipeline by EpiVax Inc, H2 2016
  • Eastern Equine Encephalitis - Pipeline by Profectus BioSciences Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Eastern Equine Encephalitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Eastern Equine Encephalitis, H2 2016
  • Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top